Recently, Medicilon Boston R&D Center has successfully passed the rigorous review by AAALAC International and achieved full AAALAC International accreditation.
Solidifying Global Development Foundation with International Standard Compliance
As a trusted global preclinical CRO platform for the pharmaceutical industry, Medicilon prioritizes quality management and ethical compliance as core development principles. With 16 years of technological expertise and continuous standard optimization, the company has obtained GLP certifications from China NMPA, the U.S. FDA and EU OECD, alongside AAALAC International accreditation, establishing a quality management system fully aligned with international norms.
Facilitating Global Innovative Drug Development and China-U.S. Dual Regulatory Filings
Global biopharmaceutical innovation accelerates rapidly, with global simultaneous development and overseas commercialization of innovative drugs becoming mainstream trends. Mutual recognition of institutional qualifications and research data remains a core barrier for enterprises’ global layout. Medicilon delivers preclinical services, including systematic in vivo pharmacodynamic studies, as well as GLP-compliant pharmacokinetic and safety assessments. Medicilon maintains nearly 1,000 efficacy models to comprehensively evaluate anti-tumor candidates: cytotoxic and targeted small molecules, mAbs, bispecific antibodies, ADCs, AOCs, CAR-T and CAR-NK cell therapies.
For non-oncology programs, Medicilon’s proprietary animal models cover inflammatory autoimmune disorders, stroke, renal ischemia-reperfusion injury, lupus erythematosus and more. These platforms support systematic testing of small molecules, biologics, ADCs, nucleic acid therapeutics, exosomes, radiopharmaceuticals and cell therapies across diverse formulations and administration routes. Medicilon also explores AI and organoid technologies to advance new drug safety evaluation.
As of the end of 2025, Medicilon has supported 651 INDs for clinical trials, among which 72 received dual US-China approvals and 17 innovative drugs launched globally.
Adhere to Research Ethics for Sustainable Industrial Development
Dr. Lin Qingcong, Executive Vice President of Medicilon and President of Medicilon USA, commented:
“Securing full AAALAC International accreditation recognizes the robust animal research quality system and management proficiency of Medicilon’s Boston R&D Center, and underscores our consistent pursuit of high research standards and global operational strategy. Adhering to the core values of Science, Standardization, Integrity and Efficiency, Medicilon will continuously upgrade animal welfare standards and R&D service competence. We will provide globally standardized drug discovery and preclinical research support to partners worldwide and speed up innovative drug development. “
Dr. Chen Chunlin, Founder, Chairman and CEO of Medicilon, stated:
About AAALAC
